Mad Money Uncovered...
Health Care: Drugs
Pacira Pharmaceuticals Inc. (PCRX: NASDAQ)
$28.44 -1.00 | -3.40%
05/20/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 29.44 |
| 52 Week High | 30.94 |
| 52 Week Low | 9.90 |
| Avg. Daily Vol. (Mil) | 0.49 |
| Beta (3 year) | 1.46 |
| Share Related Items | |
| Mkt Cap (Mil) | 972.90 |
| Shares Out (Mil) | 33.05 |
| Float (Mil) | 18.70 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 9.10 |
| Current Ratio | 10.20 |
| LT Debt/ Equity | 1.37 |
| Total Debt / Equity | 1.37 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 22.70 |
| Price/Book | 13.94 |
| Price/Cash Flow | -17.30 |
| Per Share Data | |
| Earnings | -1.98 |
| Sales | 1.30 |
| Book Value | 2.11 |
| Cash Flow | -1.70 |
| Business Summary | |
|---|---|
| General Information | |
| 5 Sylvan Way
Suite 125 Parsippany, NJ 07054 |
|
| www.pacira.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 133 | |
| CEO: David M. Stack | |
| Short Interest | |
| Current Month (Mil) | 6.03 |
| Previous Month (Mil) | 6.03 |
| Short Interest Ratio (Days) | 18.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -34.30 |
| Return on Investments | -38.00 |
| Profitability | |
| Gross Margin | 30.40 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with PCRX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserNew
- ContributorUnder-$10 Setting Up To Tra...
- UserDayTrading Test 1
- Contributor10 Best-Performing IPOs of ...
- Contributor10 Health-Care Stocks Outpe...
Latest PCRX Headlines from TheStreet
- Top Insider Trades: AGCO ECHO PCRX TWER 03.26.13 | 04:03 pm
- Top Insider Trades: CHDN, PCRX, ULTA, PMBC 03.22.13 | 08:03 am
- 'Mad Money' Lightning Round: Stick With Cummins, Sell Micron 03.14.13 | 06:03 am
- Cramer's 'Mad Money' Recap: A Resting Bull Market 03.13.13 | 07:03 pm
- Pacira Pharmaceuticals Inc. Stock Upgraded (PCRX) 03.11.13 | 05:03 am
- 4 Stocks Rising on Unusual Volume 02.01.13 | 03:02 pm
- Top Insider Trades: BAC LGND PCRX BDBD 01.28.13 | 08:01 am
- 9 Hedge Fund Favorites With Barclays Buy Ratings Test 1 11.19.12 | 06:11 am
- 9 Hedge Fund Favorites With Barclays Buy Ratings 11.16.12 | 04:11 pm
- 7 Stocks Ripping Higher on Huge Volume 06.11.12 | 01:06 pm
Press Releases for PCRX
- Analysis Of Postsurgical Pain Management Finds Opioid-Related Adverse Events Drive Longer Hospital Stays, Greater Cost And Higher Likelihood Of Readmission - Business Wire 03.27.13 | 06:03 am
- Pacira Pharmaceuticals, Inc. To Present At The Barclays Global Healthcare Conference - Business Wire 03.06.13 | 06:03 am
- Pacira Pharmaceuticals, Inc. Announces Timing For 2012 Financial Results Webcast And Conference Call - Business Wire 02.28.13 | 06:02 am
- Pacira Pharmaceuticals, Inc. To Present At The Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.25.13 | 06:02 am
- Pacira Pharmaceuticals, Inc. Announces Pricing Of $110 Million Private Offering Of Convertible Senior Notes - Business Wire 01.17.13 | 08:01 am
- Pacira Pharmaceuticals, Inc. Announces Proposed Offering Of $100 Million Of Convertible Senior Notes - Business Wire 01.15.13 | 04:01 pm
- New Publication Suggests Higher Opioid Use In The Postsurgical Setting May Be Linked To Extended Hospital Stay And Increased Cost Of Care - Business Wire 12.18.12 | 06:12 am
- Http://www.aratanatherapeutics.com/ - Business Wire 12.06.12 | 06:12 am
- Pacira Pharmaceuticals, Inc. To Present At The 24th Annual Piper Jaffray Healthcare Conference - Business Wire 11.20.12 | 06:11 am
- New Data Demonstrate Reduction In Opioid Use, Hospital Cost And Length Of Stay With EXPAREL As The Foundation Of A Multimodal Regimen - Business Wire 11.20.12 | 06:11 am
Partner Headlines for PCRX
- UPDATE: Wedbush Raises PT to $32 on Pacira Pharmaceuticals on Long-Term Outlook - Benzinga 03.07.13 | 01:03 pm
- 3 Outperforming Small Caps Bought Up By Insiders And Hedge Funds - Seeking Alpha 04.13.12 | 07:04 pm
- Noteworthy Insider Buys In The Healthcare Sector Last Week - Seeking Alpha 11.29.11 | 08:11 am
- How Will Congress' Budget Cuts Affect Health Care? - Benzinga 11.21.11 | 01:11 pm
- Decision Due For Pacira's Flagship Drug EXPAREL - Seeking Alpha 10.31.11 | 08:10 am
- Biotech Catalysts for Third Quarter - Seeking Alpha 06.24.11 | 06:06 pm
- 6 Stocks With Recent CFO Buys - Seeking Alpha 02.25.11 | 08:02 am
- 7 Diverse U.S. IPOs Test Investor Appetites This Week - Seeking Alpha 02.13.11 | 06:02 am
- RPT-IPO VIEW-Biotech IPO spurt to test U.S. market - Reuters 02.06.11 | 10:02 am
- IPO VIEW-Biotech IPO spurt to test U.S. market - Reuters 02.04.11 | 07:02 pm
